Role of GALNT2 in the modulation of ENPP1 expression, insulin signaling and action: GALNT2: A novel modulator of insulin signaling by A. Marucci et al.
Biochimica et Biophysica Acta 1833 (2013) 1388–1395
Contents lists available at SciVerse ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbamcrRole of GALNT2 in the modulation of ENPP1 expression, and insulin
signaling and action
GALNT2: A novel modulator of insulin signaling
Antonella Marucci a, Flora Cozzolino b, Claudia Dimatteo a, Maria Monti b, Piero Pucci b,
Vincenzo Trischitta a,c,⁎,1, Rosa Di Paola a,⁎⁎,1
a Research Unit of Diabetes and Endocrine Diseases, IRCCS “Casa Sollievo della Sofferenza”, San Giovanni Rotondo, Italy
b CEINGE Biotecnologie Avanzate, Naples and Dipartimento di Scienze Chimiche, Università Federico II, Naples, Italy
c Department of Experimental Medicine, Sapienza University, Rome, ItalyAbbreviations: ENPP1, ectonucleotide pyrophosphat
untranslated region; GALNT2, N-acetylgalactosaminylt
receptor; PEPCK, phosphoenolpyruvate carboxykinase;
tion studies; HEK293, human embryo kidney; HepG2
GAPDH, glyceraldehyde 3-phosphate dehydrogenase
⁎ Corresponding author. Tel.: +39 0882 416259; fax:
⁎⁎ Corresponding author. Tel.: +39 0882 416276; fax:
E-mail addresses: vincenzo.trischitta@uniroma1.it (V
r.dipaola@operapadrepio.it (R. Di Paola).
1 These two authors equally supervised the entire stu
0167-4889/$ – see front matter © 2013 Elsevier B.V. Al
http://dx.doi.org/10.1016/j.bbamcr.2013.02.032a b s t r a c ta r t i c l e i n f oArticle history:
Received 18 October 2012
Received in revised form 25 February 2013
Accepted 27 February 2013
Available online 14 March 2013
Keywords:
3′UTR binding proteins
GALNT2
ENPP1
Insulin signalingEctonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) inhibits insulin signaling and action. Under-
standing the mechanisms underlying ENPP1 expression may help unravel molecular mechanisms of insulin re-
sistance. Recent data suggest a role of ENPP1-3′untraslated region (UTR), in controlling ENPP1 expression. We
sought to identify trans-acting ENPP1-3′UTR binding proteins, and investigate their role on insulin signaling.
By RNA pull-down, 49 proteins bound to ENPP1-3′UTR RNA were identiﬁed by mass spectrometry (MS).
Among these, in silico analysis of genome wide association studies and expression proﬁle datasets pointed
to N-acetylgalactosaminyltransferase 2 gene (GALNT2) for subsequent investigations. Gene expression levels
were evaluated by RT-PCR. Protein expression levels, IRS-1 and Akt phosphorylation were evaluated by
Western blot. Insulin receptor (IR) autophosphorylation was evaluated by ELISA.
GALNT2 down-regulation increased while GALNT2 over-expression reduced ENPP1 expression levels. In addi-
tion, GALNT2 down-regulation reduced insulin stimulation of IR, IRS-1 and Akt phosphorylation and insulin
inhibition of phosphoenolpyruvate carboxykinase (PEPCK) expression, a key neoglucogenetic enzyme.
Our data point to GALNT2 as a novel factor involved in the modulation of ENPP1 expression as well as insulin
signaling and action in human liver HepG2 cells.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Insulin resistance plays a major role in the pathogenesis of type 2
diabetes, pro-atherogenic dyslipidemia and cardiovascular disease,
thus imposing a tremendous burden to morbidity and mortality in
developed countries [1].
Themolecularmechanisms underlying insulin resistance aremostly
unraveled [2]. Among several molecules involved in this process, the
class II transmembrane glycoprotein ectonucleotide pyrophosphatase
phosphodiesterase 1 (ENPP1) was identiﬁed as a putative candidate.
ENPP1 binds to [3] and inhibits the insulin receptor (IR) and subsequent
downstream insulin signaling and action in both cultured cells [4–10]
and animal models [9,11,12]. In addition, ENPP1 is over-expressed inase phosphodiesterase 1; UTR,
ransferase 2 gene; IR, insulin
GWAS, genome wide associa-
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l rights reserved.several tissues of insulin-resistant subjects [13–17]. Finally, in vitro and
in vivo studies on a gain of function amino acid substitution (i.e. K121Q
polymorphism; rs1805101) provided further support to the notion that
ENPP1 affects insulin action [7,10,18–22]. Thus, unraveling the mecha-
nisms involved in themodulation of ENPP1 expressionmight help devel-
oping strategies aimed at counteracting and possibly reversing some
forms of insulin resistance.
Recent data indicated that the 3′untranslated region (UTR) of
ENPP1mRNA plays a role in controlling ENPP1 expression, suggesting
the existence of trans-acting proteins that affect ENPP1 mRNA stabil-
ity [23,24]. The aim of this study was to identify speciﬁc ENPP1-3′
UTR binding proteins by means of RNA pull-down experiments and
to investigate their potential role on affecting ENPP1 expression and
modulating insulin signaling and action in human liver cells, the ut-
most target of insulin action on glucose homeostasis.
2. Materials and methods
2.1. RNA preparation
Themost conserved region (i.e. nucleotide (nt) 2750 to nt 3176 of the
ENPP1 cDNA) of ENPP1-3′UTR (either wild type or polymorphic-“P” [25])
1389A. Marucci et al. / Biochimica et Biophysica Acta 1833 (2013) 1388–1395was obtained as previously described [24] and then used as
template. The antisense sequence of the same region was used as
control RNA.
2.2. RNA pull-down
In order to identify those proteins which speciﬁcally bind the
ENPP1-3′UTR, the RNA pull-down with adipic acid dehydrazide bead
method was used. Brieﬂy, 15 μg of ENPP1-3′UTR, “P” ENPP1-3′UTR
or control RNA, obtained as previously described [24], was placed in
a 400 μl reaction mixture containing 100 mmol/l NaOAc, pH 5.2,
and 5 mmol/l sodium m-periodate (Sigma-Aldrich, St. Louis, MO), in-
cubated for 1 h in the dark at room temperature, ethanol precipitated,
and resuspended in 100 μl of 100 mmol/l NaOAc, pH 5.2. Then 300 μl
of adipic acid dehydrazide agarose beads 50% slurry (Sigma-Aldrich,
St. Louis, MO) equilibrated in 100 mmol/l NaOAc, pH 5.2, was added
to this mixture and incubated for 12 h at 4 °C on a rotator. The RNA
that covalently immobilized onto agarose beads was pelleted, washed
twice with 1 ml of 2 mol/l NaCl, equilibrated in washing buffer
(5 mmol/l HEPES, pH 7.9, 1 mmol/l MgCl2, 0.8 mmol/l magnesium
acetate) and, ﬁnally, incubated with 3 mg of cellular protein extract
for 30 min at room temperature in 0.6 ml ﬁnal volume. Heparin
was also added to a ﬁnal concentration of 7 μg/μl. After further
washing (i.e. four times in 1.5 ml of washing buffer), proteins
retained by RNA sequences were eluted in SDS sample buffer and
fractionated by a 12.5% SDS-PAGE. Gels were stained with colloidal
blue staining kit (Invitrogen Life Technologies, Carlsbad, CA)
[26,27].
2.3. Identiﬁcation and characterizations of ENPP1-3′UTR binding proteins
Protein bands were excised from the destained gel, reduced,
alkylated and digested with trypsin [28]. Peptide mixtures were
extracted from the gel and analyzed by nano-chromatography tandem
MS (nanoLC–MS/MS) on a CHIP MS Ion Trap XCT Ultra equipped with
a capillary 1100 HPLC system and a chip cube (Agilent Technologies,
Palo Alto, CA). Peptide analysis was performed using data-dependent
acquisition of oneMS scan (mass range from400 to 2000 m/z) followed
by MS/MS scans of the three most abundant ions in each MS scan. Raw
data from nanoLC–MS/MS analyses were employed to query a
non-redundant protein database using in house MASCOT software
(Matrix Science, Boston, MA). Proteins identiﬁed in both the control
and the sample lane were discarded, whereas those proteins solely
identiﬁed in the sample and absent in the control were selected as
putative ENPP1-3′UTR interactors.
2.4. In silico analysis
In order to prioritize proteins thatwere speciﬁcally bound to ENPP1-3′
UTR and identiﬁed by mass spectrometry analysis, we interrogated and
cross-checked genome wide association studies (GWAS) and expression
proﬁle datasets. Only proteins coded by genes that satisﬁed the following
criteria were selected for further analyses:
1. Genes containing or being nearby single nucleotide polymorphisms
(SNPs) showing genome-wide association with one or more of
the following traits: adiposity measures (i.e. BMI and waist cir-
cumference), insulin resistance (i.e. homeostatic model assess-
ment of insulin resistance – HOMA-IR index – and fasting
insulin), glucose homeostasis (i.e. fasting and 2 h glucose at
OGTT and type 2 diabetes), and pro-atherogenic dyslipidemia
(i.e. triglycerides and HDL-cholesterol).
2. Genes whose expression in human and animal tissues is relevant for
glucose homeostasis (i.e. liver, skeletal muscle and adipose tissue)
was signiﬁcantly (p b 0.05) associated with at least one of the
above-mentioned trait.The in silico analysis was carried out by browsing:
• HuGENavigator/GWAS Integrator (www.hugenavigator.net/
HuGENavigator/AHitStartPage.do), a bioinformatics tool that pro-
vides robust lookup and analytic functionalities for all pub-
lished GWAS.
• NextBio (NextBio, www.nextbio.com) that allows exploring ex-
perimental data from an extensive set of public sources, covering
a broad range of techniques and therapeutic areas.
2.5. Cell culture
HEK293 (human embryo kidney) or HepG2 (human hepatoma
cell line) cells (ECACC, Salisbury, UK) were maintained at 37 °C and
5% CO2 in DMEM/F12 containing 10% FBS (EuroClone S.p.A., Milano,
Italy). Before experiments, HepG2 cells were seeded in six-well plates
and grown in DMEM/F12 complete medium for 48 h.
2.6. GALNT2 siRNA and cDNA transfections
HepG2 cells were either transfected with 10 nmol/l of small interfer-
ing RNA (siRNA) targeted against GALNT2 mRNA (ON-TARGETplus
SMARTpool Human GALNT2 L-011865-01-0005 Thermo-Scientiﬁc
Dharmacon Lafayette, CO) or with 10 nmol/l of scrambled siRNA
(ON-TARGETplus non-targeting Pool D-001810-10-20 Thermo-Scientiﬁc
Dharmacon Lafayette, CO) by using Interferin™ Transfection Reagents
(Polyplus, Illkirch, France), according to the manufacturer's instructions.
After 48 or 96 h treatment, followed by cell lysis, equal amount of pro-
teins was analyzed by Western blot as described below.
Otherwise, HepG2 were transiently transfected either with empty
vector (mock cells) or with GALNT2 cDNA Myc/DDK tagged, cloned in
pCMV6 Entry vector TrueORF Gold (OriGene Technologies, Rockville,
MD) (GALNT2 cells), by using TransIT Reagent (Mirus, Madison,
WI), according to the manufacturer's instructions.
2.7. RNA extraction, cDNA synthesis, and gene expression analysis
Total RNA was isolated from cells using RNeasy Mini kit (Qiagen
S.r.l., Milan, Italy). cDNA was generated by reverse transcription with
iScript™ Reverse Transcription (Biorad, Hercules, CA) according to the
manufacturer's instructions and used as template in the subsequent
analyses. Gene Expression Assay on Demand Kit Reagents (Applera
Life Technologies, Carlsbad, CA) or PrimeTime Std qPCR Assay (IDT,
San Jose, CA) were used to quantify relative gene expression levels of
ENPP1, PEPCK (phosphoenolpyruvate carboxykinase) and GAPDH (glyc-
eraldehyde 3-phosphate dehydrogenase) on ABI-PRISM 7500 (Applera
Life Technologies, Carlsbad, CA). Expression levels of ENPP1 and PEPCK
were calculated by using the comparative ΔCT method. Brieﬂy, the
amount of ENPP1 and PEPCKwere normalized to GAPDH as endogenous
reference (2−ΔCT) in experiments run in triplicate and expressed as per-
centage of control cells of the ﬁrst of several experiments.
2.8. Antibodies
Antibody directed against GALNT2 was obtained from Abcam
(Cambridge, UK). Anti-ENPP1 anti-GAPDH and anti-IR β-subunit
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-Phospho-IRS-1 Tyr895, anti-IRS-1, anti-Phospho-Akt Ser473 and
anti-Akt, antibodies were purchased from Cell signaling (Boston, MA).
2.9. Western blot analysis
Cell lysateswere separated by SDS-PAGE and transferred to nitrocel-
lulosemembrane (AmershamPharmacia Biotech, Piscataway, NJ). After
blotting with speciﬁc antibodies described above, immunocomplexes
were detected with the Super Signal West Pico (Thermo Fisher
Fig. 1. SDS-PAGE of RNA protein pulled-down. HEK293 total protein extract was incu-
bated with either agarose beads alone (lane 1) or ENPP1-3′UTR RNA (lane 2) or control
RNA (lane 3) covalently linked to agarose beads. The complex were eluted with SDS
sample buffer, loaded on 12.5% SDS-PAGE, separated by electrophoresis and stained
with colloidal blue staining kit. Entire lanes observed in the gel were cut in slices and
submitted to the identiﬁcation procedure as described in Materials and methods.
1390 A. Marucci et al. / Biochimica et Biophysica Acta 1833 (2013) 1388–1395Scientiﬁc Pierce, Rockford, IL). Gel images were acquired by Molecular
Imager ChemiDoc XRS (Biorad, Hercules, CA) and band intensities
were measured by Kodak Molecular Imaging Software 4.0 as Optical
Density (OD) values. ENPP1 protein expression was evaluated by
ENPP1/GAPDH OD ratio and expressed as means ± SD. IRS-1-Tyr895
and Akt-Ser473 phosphorylations were calculated as IRS-1-Tyr895
phosphorylation/IRS-1 or Akt-Ser473 phosphorylation/Akt OD ratio re-
spectively and expressed as means ± SD.
2.10. IR β-subunit autophosphorylation
After 18 h starvation, both GALNT2 silenced and GALNT2 transfected
as well as their respective control HepG2 cells were stimulated with
100 nmol/l insulin for 5 min and lysed. IR β-subunit autophosphoryl-
ation was analyzed by using CST's PathScan Phospho-Insulin Receptor
β (Tyr1150/1151) solid phase sandwich enzyme-linked immunosorbent
assay (ELISA) Kit according to manufacturer's instruction (Cell signaling,
Boston, MA). Brieﬂy, equal amount of proteinwas incubatedwith a coat-
ed anti-Insulin Receptor β mouse antibody in order to capture both
phospho- and nonphospho-insulin receptor proteins. Following exten-
sive washing, anti-phospho Insulin Receptor β (Tyr1150/1151) rabbit
antibody is added to detect the captured phospho-insulin receptor pro-
tein. Anti-rabbit IgG, HRP-linked antibody is then used to recognize the
bound detection antibody. OD values were used as a measure of IR
β-subunit autophosphorylation. Data are means ± SD.
2.11. IRS-1-Tyr895 and Akt-Ser473phosphorylation
After 18 h starvation, GALNT2 silenced or not silenced HepG2 cells
were stimulated with 100 nmol/l insulin for 5 min and lysed; then,
equal amount of proteins was analyzed by Western blot and probed
with anti-Phospho-IRS-1 Tyr895, anti-Phospho-Akt Ser473, anti IRS-1
or anti-Akt. IRS-1 and Akt phosphorylation levels were normalized
against IRS-1 or Akt content and expressed as described above.
2.12. PEPCK mRNA expression levels
Insulin action on glucose metabolism was assessed by studying
mRNA level of the gluconeogenetic enzyme PEPCK in HepG2 cells.
After 18 h starvation, silenced or not silenced HepG2 cells were stimu-
lated with 100 nmol/l insulin for 10 h. Total RNA extraction and cDNA
synthesis and PEPCKmRNA level measurementwere performed as pre-
viously reported [10] and calculated as described above.
2.13. Statistical analyses
Differences between the mean values were evaluated by Student's
t test. Data are presented as means ± SD. SPSS 13 software package
was used for all analyses.
3. Results
3.1. Identiﬁcation and characterization of GALNT2 as an ENPP1-3′UTR
binding proteins
Proteins that speciﬁcally bind the ENPP1-3′UTR were identiﬁed by
a functional proteomic approach using afﬁnity capture and tandem
MS. Fig. 1 shows the corresponding gel stained with colloidal blue
Coomassie. The entire sample and control lanes of the gel were cut
in slices and proteins occurring in each slice were identiﬁed by
tandem-MS. Common proteins identiﬁed in both the sample and
the control gel slices were eliminated, thus greatly decreasing the
number of false positives. A total of forty-nine putative candidate pro-
teins were identiﬁed (Supplementary Table 1).
A screening procedure was applied to the list of identiﬁed proteins
to select the most promising 3′UTR interactors by interrogatingGWAS and expression proﬁle datasets using the selection criteria de-
scribed in Materials and methods. Among the forty-nine putative pro-
tein interactors, ten matched the inclusion criteria at the GWAS
dataset, whereas only two proteins were selected when using the ex-
pression proﬁle datasets. When data from the two screening proce-
dures were cross-checked, only GALNT2 matched inclusion criteria
at both datasets and was, then, selected for subsequent investigation.
The GALNT2 gene codes for an UDP-N-acetyl-alpha-D-galactosamine
polypeptide N-acetylgalactosaminyltransferase (O-GalNAc) which
contributes to the initiation of mucin-type O-linked glycosylation
[29].
3.2. Conﬁrmation of GALNT2-ENPP1-3′UTR interaction
The interaction of GALNT2with ENPP1-3′UTR RNAwas conﬁrmed by
an additional RNA pull-down assay from HEK293 total protein extract
followed byWestern-blot analysis (Fig. 2). By using anti-GALNT2 specif-
ic antibody, a clear band was detected in RNA pulled-down human
HEK293 cells (Fig. 2 panel A lane 2, n = 2), thus conﬁrming that
GALNT2 binds to ENPP1-3′UTR. The interaction between ENPP1 and
GALNT2 was further conﬁrmed in typical human insulin target cells,
namely liver HepG2 cells (Fig. 2 panel B). Such binding was not
inﬂuenced by the polymorphic “P” 3′UTR haplotype (Supplementary
Fig. 1), reported to affect ENPP1 mRNA expression [25].
3.3. Role of GALNT2 downregulation on ENPP1 expression and on insulin
signaling and action
Exposure of HepG2 cells to GALNT2 siRNA for both 48 and 96 h al-
most abolished GALNT2 expression as compared to scrambled siRNA
transfected cells (Fig. 3, panel A: lanes 2 vs. 1, n = 3 and lanes 4 vs. 3,
n = 5, respectively). As compared to scrambled siRNA transfected
cells, in GALNT2 downregulated cells (Fig. 3, panel B), ENPP1 expres-
sion tended to be increased at 48 h (i.e. 43% increase, p = 0.05–0.1),
and was signiﬁcantly increased at 96 h (116% increase, p b 0.05). Co-
herently, although to a lesser extent, also ENPP1 protein level was in-
creased at 96 h in GALNT2 downregulated as compared to control
cells (27% increase, p b 0.01, Fig. 3, panel C).
Given thewell established inhibitory role of ENPP1 on insulin signal-
ing and action [10], we tested the effect of GALNT2 downregulation on
such pathways. After GALNT2 downregulation, insulin-induced IR
Fig. 2. GALNT2/ENPP1-3′UTR interaction in HEK293 and HepG2 cells. RNA pull-down
was performed as described in Materials and methods. Following incubation with
3 mg of HEK293 (panel A), or HepG2 (panel B) total cell lysates, pulled-down proteins
with either ENPP1-3′UTR, or control RNA were analyzed by Western blot with
anti-GALNT2 speciﬁc antibody. A clear band was evident in ENPP1-3′UTR (lane 2,
panels A and B) pulled-down proteins while no band was detectable in control RNA
pulled-down proteins (lane 3, panels A and B). GALNT2 expression in 50 μg of total
cell lysate is shown in lane 1, panels A and B.
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duced as compared to insulin-stimulated scrambled siRNA cells (23%
reduction, p b 0.05). IR protein content was superimposable across all
different experimental conditions (Fig. 4 panel A). In GALNT2 siRNA
cells also IRS-1 Tyr895 (Fig. 5, panel A) and Akt-Ser473 (Fig. 5, panel B)
phosphorylations were signiﬁcantly reduced as compared to whatFig. 3. Effect of GALNT2 siRNA on ENPP1 expression. A. HepG2 cells were transfected with
methods. Expression of GALNT2 (upper blot) and GAPDH (lower blot) was evaluated by W
resentative blot for each condition is shown. B. HepG2 cells were either treated with scram
were measured by Real-Time PCR as described inMaterials and methods. Data are expressed
(n = 5) respectively. Data are means ± SD. *p b 0.05. C. HepG2 cells were either transfe
methods. Equal amount of protein from cell lysates was separated by SDS-PAGE and prob
ENPP1/GAPDH OD ratio (representative immunoblots are shown in lower panel). Data areobserved in insulin-stimulated scrambled siRNA cells (25% reduction
p b 0.01 and 57% reduction p b 0.05 respectively).
Insulin signiﬁcantly suppressed gluconeogenetic enzyme PEPCK
mRNA levels in scrambled siRNA cells (54% reduction, p b 0.01).
This effect was partially lost in GALNT2 siRNA HepG2 cells in which
only a 33% reduction of PEPCK mRNA levels was found (p = not sig-
niﬁcant vs. non insulin stimulated cells; Fig. 6). In addition, PEPCK
mRNA levels in scrambled siRNA insulin-stimulated cells were signif-
icantly lower than those in GALNT2 siRNA insulin-stimulated cells
(p b 0.05, Fig. 6). Thus, the observed deleterious effect of GALNT2
downregulation on ENPP1 expression is paralleled by a similar effect
on downstream insulin signaling and action on glucose metabolism.
3.4. Role of GALNT2 upregulation on ENPP1 expression and on insulin
signaling
Exposure of HepG2 cells to GALNT2 cDNA for 96 h, which almost
doubled GALNT2 expression (Fig. 7, panel A), reduced ENPP1 mRNA
expression levels by 30% as compared to mock HepG2 control cells
(p b 0.01, Fig. 7, panel B), thus mirroring the data obtained by
GALNT2 downregulation. In contrast, GALNT2 upregulation did not
affect ENPP1 protein content as shown in Fig. 7, panel C. This lack of
effect is observed despite the maintained ability of transfected
GALNT2 to bind ENPP1-3′UTR (Supplementary Fig. 2). Conversely,
these apparently discordant results may be due to a high ENPP1
protein stability in HepG2 cells which makes it difﬁcult to detect any
effect of ENPP1 mRNA reduction due to GALNT2 overexpression. To
test this hypothesis, we exposed cells to ENPP1 siRNA for 96 h and
then measured both ENPP1 mRNA and protein content. While ENPP1
mRNA expression levels were decreased by 39 ± 12% as compared to
scrambled siRNA HepG2 transfected cells (n = 3 experiments,either scrambled siRNA or GALNT2 siRNA for 48 or 96 h, as described in Materials and
estern blot by using anti-GALNT2 or anti-GAPDH speciﬁc antibody respectively. A rep-
bled siRNA (black bar) or GALNT2 siRNA (gray bar) and ENPP1 mRNA expression levels
as percentage of scrambled siRNA cells of the ﬁrst experiment at 48 h (n = 3) and 96 h
cted with scrambled siRNA or GALNT2 siRNA for 96 h, as described in Materials and
ed with anti-ENPP1 and anti-GAPDH speciﬁc antibody. Bars (upper panel) represent
means ± SD of 6 experiments in separate times. §p b 0.01.
Fig. 4. Effect of GALNT2 siRNA on IR β-subunit autophosphorylation. HepG2 cells were either
transfectedwith scrambled siRNAorGALNT2 siRNA for 96 hand then stimulatedwith insulin
as described inMaterials andmethods. A. Equal amount of protein from cell lysateswas sep-
arated by SDS-PAGE. IR and GAPDH protein contentwas evaluated byWestern blot by using
anti-IR β-subunit or anti-GAPDH speciﬁc antibody, respectively (a representative blot out of
3 experiments for each condition is shown). B. Bars represent OD values of IR β-subunit au-
tophosphorylation as assessed by ELISA (see Materials and methods). Data are means ± SD
of 3 experiments in separate times. *p b 0.05.
Fig. 5. Effect of GALNT2 siRNA on IRS-1-Y895 and Akt-S473 phosphorylation. HepG2 cells were
with insulin as described in Materials and methods. Equal amount of protein from cell lysa
both IRS-1 and GAPDH protein content were evaluated by Western blot analysis by using a
(upper panel) represent quantitative analysis of IRS-1-Y895 phosphorylation calculated as IRS
arate times. §p b 0.01. B. Insulin stimulated Akt-Ser473 phosphorylation and both Akt a
phospho-Akt-Ser473, anti-Akt or anti-GAPDH speciﬁc antibody, respectively. Bars (upper
Akt-Ser473 phosphorylation/Akt OD ratio. Data are means ± SD of 3 experiments in separa
Fig. 6. Effect of GALNT2 siRNA on PEPCK expression. HepG2 cells were either
transfected with scrambled siRNA or GALNT2 siRNA for 96 h and stimulated with insu-
lin as described in Materials and methods. PEPCK mRNA expression levels were mea-
sured by Real-Time PCR, as described in Materials and methods and expressed as
percentage of unstimulated scrambled siRNA cells of the ﬁrst experiment. Data are
means ± SD of 4 experiments in separate times. *p b 0.05 and §p b 0.01.
1392 A. Marucci et al. / Biochimica et Biophysica Acta 1833 (2013) 1388–1395p b 0.05), ENPP1 protein content was totally unaffected (110 ± 15% as
compared to scrambled siRNA cells, n = 3 experiments, p b 0.05), thus
reinforcing the hypothesis of a high ENPP1 protein stability, which does
not allow to appreciate variation in protein level, at least under these
experimental conditions.either transfected with scrambled siRNA or GALNT2 siRNA for 96 h and then stimulated
tes was separated by SDS-PAGE. A. Insulin stimulated IRS-1-Y895 phosphorylation and
nti phospho-IRS-1-Y895, anti-IRS-1 or anti-GAPDH speciﬁc antibody, respectively. Bars
-1-Y895 phosphorylation/IRS-1 OD ratio. Data are means ± SD of 4 experiments in sep-
nd GAPDH protein content were evaluated by Western blot analysis by using anti
panel) represent quantitative analysis of Akt-Ser473 phosphorylation calculated as
te times. *p b 0.05.
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induced IR β-subunit autophosphorylation was similar in GALNT2
overexpression and mock HepG2 control cells (Fig. 8 panel B). IR protein
content was superimposable across all different experimental conditions
(Fig. 8 panel A). Basedupon these negative results no further experiments
on downstream insulin signaling were carried out.Fig. 8. Effect of GALNT2 transfection on IR β-subunit autophosphorylation. HepG2 cells
were either transfected with mock or with GALNT2 cDNA and then stimulated with in-
sulin as described in Materials and methods. A. Equal amount of protein from cell ly-
sates was separated by SDS-PAGE. IR and GAPDH protein content was evaluated by
Western blot by using anti-IR β-subunit or anti-GAPDH speciﬁc antibody, respectively
(a representative blot out of 3 experiments for each condition is shown). B. Bars repre-
sent OD values of IR β-subunit autophosphorylation as assessed by ELISA (see Mate-
rials and methods). Data are means ± SD of 3 experiments in separate times.4. Discussion
Functional [4,7,10] metabolic [13,14,16] and genetic [18,23,25,30–38]
studies suggest that ENPP1 acts as a negative modulator of insulin signal-
ing and action. Thus, addressing the mechanisms underlying ENPP1
expression may help unravel novel molecular mechanisms of insulin
resistance.
Our study on human liver HepG2 cells shows that GALNT2 binds to
ENPP1-3′UTR mRNA and inhibits ENPP1 transcript and protein levels.
This ﬁnding adds to previous functional [24,25] and genetic [23,25]
reports suggesting that, in fact, the 3′UTR is involved in the regulation
of ENPP1 expression in human liver cells, the utmost target of insulin
action on glucose homeostasis. Of note, a previously reported 3′UTR
polymorphic haplotype did not impair GALNT2 binding afﬁnity, thus
suggesting that its effect on ENPP1mRNA levels [25] is not mediated by
GALNT2. Whether other SNPs associated with metabolic traits [23]
which are located outside the most conserved 3′UTR we used for our
experiments, affect GALNT2 binding may be interested to be addressed
by further investigations. Also of note is that HSP70 was not identiﬁed
as a binding protein of ENPP1-3′UTR, a ﬁnding which is in contrast
with our previous reports [24]. We like to speculate that the different
methods utilized in our present and previous studies (RNA-pull-down
vs. RNA Mobility Shift Analysis) underline the different results we
obtained.
A second important ﬁnding of this study is that GALNT2
downregulation affects insulin-induced IR β-subunit autophos-
phorylation, IRS-1 Tyr895 and Akt Ser473 phosphorylations and
PEPCK expression, four key steps of insulin signaling and gluconeogeneticFig. 7. Effect of GALNT2 transfection on ENPP1 expression. A. HepG2 cells were either transfected with mock or with GALNT2 cDNA as described in Materials and methods. Equal
amount of protein from cell lysates was separated by SDS-PAGE and probed with anti-GALNT2 (upper blot) or anti-GAPDH (lower blot) speciﬁc antibody. A representative blot
out of 3 experiments for each condition is shown. B. ENPP1 expression levels were measured by Real-Time PCR as described in Materials and methods and expressed as percentage
of mock HepG2 cells of the ﬁrst experiment. Data are means ± SD of 3 experiments in separate times. §p b 0.01. C. HepG2 cells were either transfected with mock or with GALNT2
cDNA as described in Materials and methods. Equal amount of protein from cell lysates was separated by SDS-PAGE and probed with anti-ENPP1 and anti-GAPDH speciﬁc antibody.
Bars (upper panel) represent ENPP1/GAPDH OD ratio (representative immunoblots are shown in lower panel). Data are means ± SD of 3 experiments in separate times.
1394 A. Marucci et al. / Biochimica et Biophysica Acta 1833 (2013) 1388–1395activity. These effects are very likely mediated, by ENPP1 protein
up-regulation. In fact, GALNT2 overexpression, which down-regulates
ENPP1mRNA levels but not ENPP1 protein content, is not paralleled by
any change of insulin-induced IR β-subunit autophosphorylation. This
ﬁnding reinforces the hypothesis that ENPP1 up-regulation, mediates,
at least partly, GALNT2 down-regulation effects on insulin signaling
and action. We acknowledge that further experiments using cellular
models lacking both ENPP1 alleles, are needed to deﬁnitively conﬁrm
such hypothesis.
It is entirely possible that other mechanisms also underlie such
GALNT2 effects. As a matter of fact, GalNAc-T2 coded by GALNT2 is
responsible for the O-linked glycosylation, allowing the transfer of
N-acetylgalactosamine from UDP-GalNAc to the hydroxyl group of a
serine or threonine residue [29]. Such glycosylation has been reported
to play an important role on insulin resistance and diabetes, either by
competing for phosphorylation on insulin-stimulated sites on effector
molecules, or by directly regulating components of insulin signaling, in-
cluding IRS1 and Akt [39–42].
Regardless the mechanism of action, also data from the few stud-
ies so far published on GALNT2 expression levels in several models of
metabolic abnormalities related to insulin resistance suggests that it
modulates insulin resistance traits. While GALNT2 expression is re-
duced in liver of insulin resistant Goto-Kakizaki diabetic rats [43], it
is increased in adipose tissue of obese, insulin resistant non-diabetic
PIMA Indians [44]. In addition, GALNT2 expression in mice causes an
inverse modulation of serum HDL-c levels, an established marker of
insulin sensitivity [45]. All in all, expression data in both humans
and rodents, although somehow variable, clearly point to GALNT2 as
a potential mediator of abnormalities related to insulin resistance.
Further support to this hypothesis comes from studies showing that
genetic variability at the GALNT2 locus (SNP rs4846914) is associated
with decreased HDL-c and increased triglyceride levels [46–48], two
main components of the insulin resistance/metabolic syndrome.5. Conclusions
In conclusion, our data identiﬁed GALNT2 as a newpotentialmodula-
tor of insulin signaling and action in human liver cells through the mod-
ulation of ENPP1 expression. Additional experiments in other cell types
and tissues relevant to glucose metabolism are needed to conﬁrm this
ﬁnding, thus deeper addressing the role of GALNT2 as a potential target
of novel treatments of insulin resistance and abnormal glucose homeo-
stasis. Finally, because of the very restrictive prioritizing criteria we
used to identify GALNT2, the list of ENPP1-3′UTR binding proteins may,
in fact, contain additional important candidates to be investigated in
further studies.
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